Miniatura

Fitxers

fimmu-13-855730.pdf (1.01 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-07-12

Llicència de publicació

cc by (c) Bastos Oreiro, Mariana et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/188928

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fimmu.2022.855730

Resum

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 months, p <= 0.001) and overall survival (OS) (median of 15 vs. 8 months, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44-0.80); p < 0.001] for PFS, and 0.45 [(95% CI: 0.31-0.64)] for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 versus 2.8 months, respectively, p = 0.027) and OS (58% versus 42% at 12 months, respectively, p = 0.048) than tisa-cel. These differences were maintained in the multivariable analysis. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria.

Matèries

Limfomes, Teràpia cel·lular, Cèl·lules B

Matèries (anglès)

Lymphomas, Cellular therapy, B cells

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BASTOS OREIRO, Mariana, GUTIÉRREZ GARCÍA, Antonio manuel, REGUERA, Juan luís, IACOBONI, Gloria, LÓPEZ CORRAL, Lucía, TEROL, María josé, ORTÍZ MALDONADO, Valentín, SANZ, Jaime, GUERRA DOMÍNGUEZ, Luisa, BAILEN, Rebeca, MUSSETTI, Alberto, ABRISQUETA COSTA, Pau, HERNANI, Rafael, LUZARDO, Hugo, SANCHO, Juan manuel, DELGADO SERRANO, Javier, SALAR, Antonio, GRANDE, Carlos, BENTO, Leyre, GONZÁLEZ DE VILLAMBROSÍA, Sonia, GARCÍA BELMONTE, Daniel, SUREDA, Anna, PÉREZ MARTÍNEZ, Antonio, BARBA, Pere, KWON, Mi, MARTÍN GARCÍA SANCHO, Alejandro. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. _Frontiers in Immunology_. 2022. Vol. 13, núm. 855730. [consulta: 20 de gener de 2026]. ISSN: 1664-3224. [Disponible a: https://hdl.handle.net/2445/188928]

Exportar metadades

JSON - METS

Compartir registre